Epcoritamab in B-cell malignancies: current status and prospects

Figures & data

Figure 1. Epcoritamab T cell – engagement with the CD3 receptor on T cells and the CD20 receptor on the surface of lymphoma cells. The action releases cytokines and induces B-cell lysis.

Table 1. Overview of bispecific antibodies in hematological malignancies.

Drug name	Format	Specificity	Indication	Clinical trial	Number pts.	Response in R/R disease	Phase
Blinatumomab^1	BiTE	CD19/CD3	ALL	NCT02013167	405	CR,33.6%	Marketed 2014
Mosunetuzumab (RG7828, CD20-TDB)^2	Hz IgG1-based, Fc -silent, KIH	CD20/CD3	FL	NCT02500407	90	CR,60%	Marketed 2022
Epcoritamab (GEN3013)^3	Hz/hu IgG1-based Duobody	CD20/CD3	DLBCL	NCT03625037	157	ORR,63.1%;CR,38.9%	Marketed 2023
Glofitamab (RO7082859, RG6026)^4	Hz IgG1-based 2 + 1 CrossMab	CD20/CD3	DLBCL	NCT03075696	155	ORR,52%;CR,39%	Marketed 2023
Odronextamab (REGN1979)^5	Hu IgG4-based, VelociBi	CD20/CD3	B-cell malignancies	NCT03888105	145	51%	2 (potentially pivotal)
Teclistamab (JNJ 7957)^6	Hz IgG4 Duobody	BCMA/CD3	MM	NCT04557098	165	ORR,63%;CR,39.4%	Marketed 2022
Elranatamab (PF-06863135)^7	Hz IgG2, hinge-mutation	BCMA/CD3	MM	NCT05020236	123	ORR,61%;CR,35%	In review
Linvoseltamab (REGN5458)^8	IgG4 VelociBi	BCMA/CD3	MM	NCT03761108	252	ORR,71%;CR,30%	2 (potentially pivotal)
Talquetamab (JNJ 7564)^9	Hz IgG4 Duobody	GPRC5D/CD3	MM	NCT04634552	232	ORR,70%;23%	In review

ORR, Overall Response Rate; CR, Complete Response.